IN THE NEWS

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

April 3rd, 2020|

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating   PALO ALTO, Calif. April 1, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today provided an update on the impact of the rapidly progressing global COVID-19 (SARS-CoV-2) pandemic.  Eiger has put into place remote operations and new [...]

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

March 23rd, 2020|

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO,  Calif. March 23, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has completed submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for lonafarnib for the treatment of [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

March 13th, 2020|

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA Progeria NDA Submission Complete by End of March 2020 Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif., March 13, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the fourth quarter and full [...]